Navigation Links
Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application
Date:1/31/2008

TOKYO and WOODCLIFF LAKE, N.J., Feb. 1 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) and Eisai's U.S. subsidiary, Eisai Corporation of North America (Headquarters: New Jersey, the United States, Chairman & CEO: Hajime Shimizu), today announced a change in the schedule for submission to the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) for E7389 (generic name: eribulin mesylate) for third-line treatment of advanced breast cancer in patients who were pretreated with anthracycline, taxane and capecitabine.

Eisai is committed to developing E7389 as a potential treatment for patients with advanced breast cancer. In a Phase II study of 299 patients with advanced breast cancer who had been heavily pretreated, the compound has shown promising anti-tumor activity, with a response rate of 14.1% by investigator evaluation and 9.3% by independent radiologist evaluation. It has also been shown in the Phase II study to be generally well-tolerated, with the most common Grades 3 and 4 drug-related adverse events being 54% in neutropenia and 14% in leucopenia. Grade 3 peripheral neuropathy occurred in 6% of study participants, and there were no Grade 4 events.

Eisai had planned to submit an NDA under Subpart H*, based on Phase II clinical trial data, to seek accelerated approval for E7389 as a third-line breast cancer treatment (monotherapy), but is precluded from doing so, because FDA approved another drug for this specific indication last October. Eisai remains committed to advancing two Phase III clinical trials for E7389, which are ongoing in the U.S. and in Europe, Study 301 for second-line and Study 305 for third-line breast cancer treatment. Eisai now plans to submit an NDA to FDA with data from these trials and Phase II clinical trial data in fiscal year 2009-2010. In addition, Eisai continues to evaluate E7389 as a potential treatment for a variety of other solid tumors, including non-small
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
2. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... 31, 2015 , ... Regulatory agencies have acknowledged impurities especially ... process. Thus, innovator companies must understand what will be needed in the drug ... been hosting multiple educational panels and seminars for experts to share advice concerning ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s a new treatment option for excessive ... commercially available new FDA approved system in the last 14 years, and the only ... Amenorrhea (zero bleeding) rate of 66%, the high Patient Satisfaction rate of 98%, and ...
(Date:8/30/2015)... England , August 31, 2015 /PRNewswire/ ... 51-jährige Wartezeit   einer Frau   für chirurgische   ... Alter von 7-90   werden für eine ... Programm soll 1200 Frauen behandeln und die Anzahl ausgebildeter ... Astellas gab heute bekannt, dass  Action ...
(Date:8/28/2015)... 28, 2015 According to a ... Cryogenic Storage Systems, Thawing Equipment, Alarms), by Biospecimen (Human ... Trials), End User - Global Forecast to 2020", published ... reach USD 3,731.03 Million by 2020 from USD 2,150.48 ... between 2015 and 2020. Browse 74 ...
Breaking Biology Technology:Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 5Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5
... REYKJAVIK, Iceland, April 3, 2008 U.S.,Preventive Medicine(R), ... Genetics, the global leader in gene discovery, today,announced ... add genetic testing to,expand both companies, personalized medicine ... of the letter of intent with deCODE is ...
... Research Results To Be Presented at Experimental Biology ... Wellmune WGP(R), a natural,immune-enhancing ingredient from Biothera, ... for study subjects to miss work or school ... the 2008 Experimental,Biology annual meeting., Don Cox, ...
... ,Pharmacyclics, Inc. (Nasdaq: PCYC ) today announced ... drug candidates at the,American Association for Cancer Research ... at the San Diego Convention Center in San ... histone deacetylase(HDAC),inhibitor, which is now in a multicenter ...
Cached Biology Technology:U.S. Preventive Medicine and deCODE Genetics Sign Letter of Intent to Expand Personalized Medicine Platform 2U.S. Preventive Medicine and deCODE Genetics Sign Letter of Intent to Expand Personalized Medicine Platform 3Wellmune WGP(R) Supplementation Alleviates Duration, Severity and 'Down Time' Due to Cold Symptoms 2Wellmune WGP(R) Supplementation Alleviates Duration, Severity and 'Down Time' Due to Cold Symptoms 3Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting 2Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting 3Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting 4
(Date:8/31/2015)... -- Growing need for data security coupled ... to drive India biometrics market   ... " India Biometrics Market Forecast & Opportunities, 2020 ", biometrics ... grow at a CAGR of over 35% during 2015 - ... extensive use of biometric technology in the government sector. Ongoing ...
(Date:8/24/2015)... , August 24, 2015 The ... ,s largest biometrics manufacturer DERMALOG and its customized solutions ... "2015 African Biometrics Company of the Year Award". DERMALOG is ... Nigeria .   -Cross reference: Picture is ... - On Thursday evening, in ...
(Date:8/19/2015)... Aug. 19, 2015  VOXX International Corporation (Nasdaq: ... entered into a Definitive Agreement to purchase the ... authentication market leader EyeLock through an acquiring entity.  ... a controlling interest in the acquiring entity. The ... of due diligence.  Expanding on its existing supply ...
Breaking Biology News(10 mins):India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 2India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 3Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
... researchers at Oregon State University, the world,s multi-billion dollar foundry ... that produces metal castings used in everything from water pumps ... thousands of years to before Greek and Roman times. It ... continues to evolve. Some modern technologies use various types ...
... Calif -- Nitrogen is a beneficial plant fertilizer in ... ecosystems, such as water pollution, acidification of soils, increased ... a decline of native plant diversity. Over the ... amount of plant-available nitrogen inputs from the atmosphere compared ...
... for Experimental Biology (FASEB) commends Air India for continuing ... company, FASEB expressed its appreciation for Air India,s perseverance ... groups to discontinue shipping laboratory animals. "Animals are crucial ... the world are dependent upon their safe and humane ...
Cached Biology News:Sweet new approach discovered to help produce metal casting parts, reduce toxicity 2Researchers to study impacts of pollutant nitrogen on plant species diversity 2
PlusOne EDTA, disodium salt, 100 g. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Buffers....
...
Normal human serum collected off the clot from healthy normal humans. Each donor unit is negative for anti-HIV 1&2, HIV-Ag, HCV, and HBsAg by FDA required tests...
Normal human AB serum, pooled...
Biology Products: